Liver Int:儿童和成人因药物引起的急性肝衰竭:128例患者的研究结果

2018-07-27 MedSci MedSci原创

14%的DILI导致了药物诱导性急性肝衰竭(DIALF)。TD、AED、氨苯砜和抗逆转录病毒是导致DILI常见的药物。自发性生存率只有34%,而ATD的死亡率更高。非ATD和非APAP药物的存活率更高(51%)。INR和MELD能够预测患者死亡率。

研究背景和目的:导致急性肝衰竭(ALF)的药物并不常见,而且在地理上也各不相同。本研究的目的是就药物诱导性ALF (DIALF)患者的相关药物、临床特点、实验室特点和结果进行综述。研究分析了死亡率的预测因素及其与MELD、King's College criteria (KCC)和ALFSG指数的关系。

研究方法:该研究从药物性肝损伤(DILI)注册表(1997-2017)中确定了发生DIALF的患者。RUCAM被用于病情判断。符合急性肝衰竭和药物诱导性肝损伤的患者被纳入研究。研究主要的结果是自发性生存和死亡。

研究结果:在905例DILI患者中,128例患者属于药物诱导性急性肝衰竭(DIALF)患者。这些患者的平均年龄为38岁,68例患者为(53%)女性,21例患者为(16.4%)儿童,且年龄小于18岁。联合的抗结核药物(ATD)是导致DIALF的最主要病因。其他导致DIALF的药物是抗癫痫药物(AED, n = 11,10%),氨苯砜 (n = 7,5.5%),激素(n = 2),硫酸亚铁过量(n = 2),乙酰氨基酚(APAP) (n = 2),抗逆转录病毒(n = 2),CAM (n = 2),化疗药物(n = 3)等。44例患者(34%)自行痊愈,84例(66%)包括13名儿童(62%)死亡。女性、腹水、白蛋白、胆红素、INR和MELD与死亡率显著相关。ATD的死亡率为79%,APAP和铁过量的死亡率为100%。在ROC下,MELD和ALFSG的面积为0.76, KCC的面积为0.51。

研究结论:14%的DILI导致了药物诱导性急性肝衰竭(DIALF)。TD、AED、氨苯砜和抗逆转录病毒是导致DILI常见的药物。自发性生存率只有34%,而ATD的死亡率更高。非ATD和非APAP药物的存活率更高(51%)。INR和MELD能够预测患者死亡率。

原始出处:

Devarbhavi H, Patil M, Reddy VV, et al. Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. Liver Int, 2018, 38(7), 1322-1329.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635804, encodeId=1397163580420, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 07 10:54:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739494, encodeId=d4451e394946b, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Apr 28 23:54:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290481, encodeId=de0e12904816b, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Sun Jul 29 07:54:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334571, encodeId=73ce3345e10e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 27 20:54:43 CST 2018, time=2018-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635804, encodeId=1397163580420, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 07 10:54:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739494, encodeId=d4451e394946b, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Apr 28 23:54:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290481, encodeId=de0e12904816b, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Sun Jul 29 07:54:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334571, encodeId=73ce3345e10e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 27 20:54:43 CST 2018, time=2018-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1635804, encodeId=1397163580420, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 07 10:54:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739494, encodeId=d4451e394946b, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Apr 28 23:54:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290481, encodeId=de0e12904816b, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Sun Jul 29 07:54:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334571, encodeId=73ce3345e10e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 27 20:54:43 CST 2018, time=2018-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1635804, encodeId=1397163580420, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 07 10:54:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739494, encodeId=d4451e394946b, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Apr 28 23:54:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290481, encodeId=de0e12904816b, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Sun Jul 29 07:54:00 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334571, encodeId=73ce3345e10e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 27 20:54:43 CST 2018, time=2018-07-27, status=1, ipAttribution=)]
    2018-07-27 医者仁心5538

    学习了

    0